NEW YORK, Feb. 1 - Genaissance Pharmaceuticals and Biogen struck a deal to combine pharmacogenomic testing and drug development, the two companies said on Friday.
The aim of the deal is to pair pharmacogenomic tests with new drug targets and drugs currently in development at Biogen, and ultimately market the two in tandem.
Through the partnership, Genaissance will get an upfront cash payment, research funds, and milestone payments. The company is also eligible for downstream payments based on successful development.
Financial details were not disclosed.
The partnership will make use of Genaissance's HAP technology in order to characterize haplotypes and link these with drug responses. The company will process samples from Biogen's clinical work.
Genaissance says it has a cache of almost 100,000 haplotypes from more than 5,400 genes, and intends to discover haplotypes for all human genes.
The New Haven, Conn.-based firm began clinical trials last year to connect haplotype profiles with patient drug response to a set of cholesterol-lowering drugs. It also plans to develop its own drugs.